Gastric Cancer Diagnostics Market By Product Type (Instruments & Platforms, Assays & Kits, Reagents & Consumables, Software & Services), By Sample Type (Tissue Samples, Blood & Plasma, Gastric Juice, Stool Samples, Breath Samples), By Modality (Endoscopy & Biopsy, Histopathology & Cytology, Immunohistochemistry (IHC), Molecular & Genomic Tests, Liquid Biopsy, Imaging, Biomarker Tests), By Technology (Pathology, Genomics, Proteomics & Metabolomics, Imaging Platforms, Bioinformatics & Software Tools), By Application (Population Screening & Risk Stratification, Initial Diagnosis, Cancer Staging, Companion Diagnostics, Treatment Monitoring, MRD Surveillance, Others), By End User (Hospitals & Cancer Centers, Diagnostic & Reference Laboratories, Academic & Research Institutes, Specialty GI & Endoscopy Clinics, Contract Research Organizations (CROs) & Pharma Companies, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles And Market Forecast, 2025 – 2035.

---

What trends will shape the Gastric Cancer Diagnostics Market in the coming years?

The Gastric Cancer Diagnostics Market accounted for USD 1.22 Billion in 2024 and USD 1.31 Billion in 2025 is expected to reach USD 2.76 Billion by 2035, growing at a CAGR of around 7.71% between 2025 and 2035. The Gastric Cancer Diagnostics Market will be influenced by a range of factors including growing acceptance of liquid biopsy and ctDNA testing for non-invasive diagnosis, increasing adoption of NGS and molecular profiling to identify precision therapy, greater prevalence of AI and digital pathology for more rapid and accurate diagnosis, expansion of screening programs in high-risk areas, increasing demand for companion diagnostics associated with targeted therapies, innovations in minimally invasive endoscopic techniques, and the growing awareness of early detection and personalized therapies across health systems worldwide.

What do industry experts say about the Gastric Cancer Diagnostics market trends?

“By combining the sensitivity of cell-free microRNAs with the specificity of exosomal markers, DEX-G2 offers a minimally invasive, accessible, and highly accurate method for detecting gastric cancer at a stage when outcomes can be dramatically improved.”

• Dr. Ajay Goel, developer of the DEX-G2 test.

"Between life sciences and clinical application, our market is growing, so saying 7% means outpacing the market and therefore taking market share."

• Thierry Bernard, CEO of Qiagen.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Gastric Cancer Diagnostics market?

How does the increasing prevalence of gastric cancer globally fuel the adoption of advanced diagnostics?

The Gastric Cancer Diagnostics Market is seeing a swift embrace of improved diagnostic technologies driven by the increasing prevalence of gastric cancer across the globe. Globocan 2020 estimates the incidence of stomach cancer at approximately 1.1 million newly diagnosed cases across the globe, which accounts for 5.6% of all cancer diagnoses. The high incidence of gastric cancer strengthens the need for effective early detection methods and, equally important, more accurate methods of detection. Approximately 75% of new cases diagnosed and deaths are in Asia, specifically Japan, China, and South Korea, putting pressure on the health-care systems struggling with the disease burden.

The growing number of patients is leading to the demand for endoscopy and other diagnostic methods, including molecular diagnostic testing and liquid biopsy. Each method can detect the disease in its early and more treatable stages of gastric cancer to increase the patient's chance of survival. Improvements in artificial intelligence capabilities and digital pathology tools allow for better detection, further reducing the amount of human error in analysis and allowing for significant improvements in analysis workflows. These diagnostic capabilities will enable health care systems to meet their rising disease burden. The combination of advancing technology, accompanied by a rising prevalence of the disease, is a major source of growth moving forward, as the global disease burden drives the widespread adoption of more advanced diagnostics in clinical practice.

How is the rising demand for non-invasive diagnostic tests improving early detection effectively?

The Gastric Cancer Diagnostics Market is experiencing accelerated growth driven by the demand for non-invasive diagnostic tests, which have tremendous potential to aid early detection of gastric cancer. According to the U.S. National Cancer Institute, non-invasive blood tests have already detected cancer in patients who were asymptomatic at the time of the tests, revealing cancer one to four years ahead of traditional diagnostic tests. Rarely is early detection so significant, as the region with one of the highest levels of gastric cancer is the East Asia region, where the early detection of gastric cancer substantially improves survival rates. Non-invasive diagnostic tests such as liquid biopsy, breath analysis, and stool-based DNA tests are preferred to the more traditional incisional methods because they make the testing experience far less invasive and provide less risk to the patient while being much more cost-effective, as the tests are not only less invasive but also easier to access. Non-invasive tests have the added advantages of greater follow-up, as patients are much more willing to submit to follow-up testing, as it is more comfortable, less risky, and less costly.

Although research in this area indicates that the incorporation of artificial intelligence in the interpretation of the test results will not necessarily improve the test outcomes, others have suggested quite the opposite, as artificial intelligence was used more as a quality assurance measure to improve workflow efficiency. The healthcare systems and hospitals alike face an overwhelming increase in disease burden, and their health systems are systematically rolling out these testing solutions to systematically care for these disease burdens. Non-invasive testing provides the healthcare team with the ability to plan for the interventions of care sooner and help determine treatment action plans sooner to enhance the level of care provided to patients. Significantly, the expectations of advanced testing are driving the growth of the gastric cancer diagnostics market.

How does the high cost of advanced diagnostic equipment limit accessibility in developing regions?

The Gastric Cancer Diagnostics Market is held back by considerable restraints on the accessibility and availability of sophisticated diagnostic equipment in developing and low-income countries due to expense. Generally, advanced diagnostic methods include advanced training and standards for personnel and costlier operational methodologies (and a heavier burden for quality control), and because of these expenses, the procurement of sophisticated tools (liquid biopsy platforms, molecular testing kits) and the purchase of equipment (AI-enabled maps, etc.) all require high capital spending. For example, considerable expense may be incurred in maintaining hospital quality, and health care costs may restrict access to advanced diagnostic technologies and knowledge in developing regions.

For instance, if healthcare resources are scarce, as they may be in low- and middle-income countries, patients would need to rely on the last-minute lengths of ambiguity to detect gastric cancer and perhaps wait to rely on the traditional PET scan or other imaging for gastric cancer determination. In time, the patient may discover they have late-stage cancer, but the issue at hand would be no implementation of an advanced diagnostic approach, which warrants the findings. The health care biases between agents in the highest-level income countries and lower economies were then contributing to high-level adaptations to technological availability. The issue rests with the price of advanced diagnostic equipment, which is certainly a barrier to market development in third-world countries. Hence, the price means even more to the work described above, so that in most cases, the economic burden of the process remains a challenge to the approach for stomach cancer patients.

How do emerging markets provide potential for expansion due to healthcare awareness growth?

The Gastric Cancer Diagnostics Market continues to grow in emerging markets due to an increase in healthcare awareness. In India alone, out of approximately 1.6 million reported new cases of gastric cancer per year, it is imperative to detect cases early and implement screening programs. The increase in the general public's awareness is pushing up engagement in preventive health programs, especially in rural and demographically underserved areas. Community health workers, such as Accredited Social Health Activists (ASHAs), are fostering development by spreading information on early symptoms and making small lifestyle changes.

National campaigns and interventions, or government-led initiatives, are also focusing on early diagnosis and appointment of timely treatment options. The private sector is also adjusting to accommodate a growing interest in affordable diagnostic technologies. Partnerships between international agencies and local providers are strengthening capabilities and improving training infrastructure to subsequently offer appropriate testing. Now that there is improved access to diagnostic centers, outreach programs are connecting previously inaccessible people in towns and rural communities to testing programs (and outreach testing provision models), which enable many more people to be regularly screened. As general awareness extends, rates of early detection and patient outcomes have significantly increased. Therefore, the growth of healthcare consciousness, as seen in emerging markets, is a major contributor to the growth of the gastric cancer diagnostics market.

How does the development of companion diagnostics enable personalized therapy for better treatment outcomes?

The development of companion diagnostics has led to significant growth opportunities in the Gastric Cancer Diagnostics Market, as these tests allow for personalized treatment plans, leading to better treatment outcomes. Companion diagnostics are specialized tests used to decide if a specific therapeutic product is appropriate for an individual patient in order to ensure a targeted and effective therapy. These diagnostics then detect the presence of selected genetic mutations or biomarkers in tumors that can be used by the clinician in disease therapy selection in order to make the best selection of therapies. For instance, solid tumors are tested for DNA mismatch repair deficiency with FDA-approved companion diagnostic tests that direct the application of immunotherapy treatment.

In gastric cancer, those biomarkers have enabled the confirmation of specific genetic alterations, assisting in the provision of individualized treatment plans, thus increasing treatment response rates and prolonging survival. Companion diagnostics also enable the monitoring over time of the effectiveness of therapies, enabling early therapeutic changes if necessary. By eliminating unnecessary exposure to ineffective treatment, they accelerate overall patient safety and reduce unnecessary side effects. Use of companion diagnostics in conjunction with clinical practice enables precision medicine algorithmic approaches to be tailored to the individual patient. As the field of personalized medicine continues to develop, these types of diagnostics are becoming integral to oncology care. Overall, companion diagnostics have become an essential factor in driving targeted therapy and optimizing therapeutic output within the gastric cancer diagnostics market.

What are the key market segments in the Gastric Cancer Diagnostics industry?

Based on the product type, the Gastric Cancer Diagnostics Market is classified into Instruments & Platforms, Assays & Kits, Reagents & Consumables, and Software & Services. Instruments & Platforms is composed of any system used to detect gastric cancer, such as endoscopy systems, imaging systems, and laboratory analyzers. Assays & Kits consist of molecular tests, immunohistochemistry panels, and any other kits designed to facilitate the detection of gastric cancer accurately.

Reagents & consumables are anything that can be used in the laboratory, such as antibodies, primers, probes, and any other materials needed to complete a lab test. Software & Services consists of bioinformatics software applications, nimble and AI-based analysis platforms, and digital pathology-related offerings used to help doctors and clinicians make a diagnosis and create a report. The product types of Instruments & Platforms, Assays & Kits, Reagents & Consumables, and Software & Services work together to support early detection, monitor treatments, and use precision medicine.

Based on the application, the Gastric Cancer Diagnostics Market is classified into Pathology, Genomics, Proteomics & Metabolomics, Imaging Platforms, and Bioinformatics & Software Tools. In pathology, cancerous changes are identified through tissue analysis, histopathology, and immunohistochemistry. In contrast, genomics includes molecular profiling, gene panels, and sequencing techniques that are conducted to create an appropriate precision diagnosis. Proteomics & Metabolomics can be used to determine levels of proteins expressed in the tissue and metabolic signatures, and the analysis of tissues to identify the disease biomarker of interest.

Imaging platforms are technologies such as CT, MRI, PET-CT, and endoscopy imaging, etc., which are all useful to determine an appropriate visualization of the disease and staging in the series of diagnostic requirements. Bioinformatics and software tools are useful to support data analysis, for algorithms to determine next steps, and consequently to create documented decision points. All of the applications noted are needed to achieve the desired outcomes for early detection, personalized treatment planning, and establishing a monitoring program to assess therapeutic response. Each application wants to leverage earlier results and findings to achieve greater outcomes for the patient.

Which regions are leading the Gastric Cancer Diagnostics market, and why?

The North American Gastric Cancer Diagnostics Market is leading due to its high level of healthcare infrastructure and the adoption of innovative diagnostic technology. The United States holds the bulk of the region's market size due to the high cancer screening programs in place, established research institutions, and investment in the area of precision medicine. The role of Canada in providing the market is the increased level of attention on early cancer detection and the definition of molecular diagnostics implementation.

The presence of the key market players, such as Roche Diagnostics, Abbott Laboratories, and Qiagen, in North America supports the regional market. Government initiatives, reimbursement support, and regulatory mandates for the establishment of advanced diagnostic tools will support the adoption of advanced technologies. The impact of gastric cancer on certain segments of the population and the clear need for repetition on cancer findings will also bring more early detection solutions to market. The ongoing investment in R&D with the incorporation of AI and digital pathology will increase the efficiency and accuracy of diagnosis. Overall, North America is expected to remain one of the prominent and innovative market hubs in the gastric cancer diagnostics space.

The Asia Pacific Gastric Cancer Diagnostics Market is growing due to the high presence of gastric cancer in countries such as Japan, China, and South Korea. Growth in this part of the globe is also attributable to rising healthcare expenditures, increasing diagnostic infrastructure, higher levels of advocacy regarding early cancer detection, and rapid advancements in diagnostic technology, including molecular testing and liquid biopsies.

Initiatives from the government in Japan and South Korea, including government screening programs at a national level, foster the conditions for early diagnosis and monitoring of treatment. The emerging biotechnology companies and their partnerships with leading global market suppliers with significant interest in gastric cancer also support the regional market positively. The demand for personalized medicine and companion diagnostics is also increasing, and in some instances may include IVD diagnostics alongside these other heightened preferences.

What does the competitive landscape of the Gastric Cancer Diagnostics market look like?

The Gastric Cancer Diagnostics Market is highly durable, which leads to a competitive landscape as key players continue to promote their place in the marketplace by investing in technology developments, forging partnerships, and acquiring and launching new product portfolios. Leading companies such as Roche Diagnostics, Abbott Laboratories, Qiagen, Thermo Fisher Scientific, and NeoGenomics continue to dominate the market based on their expansive diagnostic portfolios and their international outreach. Many leading companies continually invent and invest heavily in research and development and innovations for liquid biopsies, molecular assays, and RAI-enabled diagnostics to facilitate accuracy.

Strategic planning often includes acquisitions and partnerships with the intention of continuing to broaden capabilities and enter new geographic regions. For example, in 2025, GSK acquired IDRx, a biopharmaceutical company specializing in the use of treatments for gastrointestinal cancer, to enhance its oncology pipeline in support of advanced diagnostic solutions. Other emerging companies, such as Tempus Labs and Cizzle Bio, are enhancing the market space by providing AI-driven digital pathology solutions and blood tests for early detection. Competition is not solely on commercializing individual solutions; it is related to improving workflow efficiencies and enhancing turnaround times to increase patient access for diagnosis. Commercial realities in regional markets, including regulatory approvals and reimbursement policies, will continue to impact and shape competitive strategies. Consolidation and continuous innovation in biomarker testing, companion diagnostics, and precision medicine will remain a challenge. Overall, while the Gastric Cancer Diagnostics Market is expanding with new established and emerging players, the innovation and competition will ultimately enhance technology and improve treatment and diagnosis around the world.

Gastric Cancer Diagnostics Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Gastric Cancer Diagnostics industry?

• In June 2025, Amgen Announces Positive Phase 3 Results for Bemarituzumab in Gastric Cancer. Amgen reported positive topline results from a Phase 3 study of bemarituzumab in combination with chemotherapy and nivolumab for first-line gastric cancer. The study demonstrated significant efficacy, with a data readout anticipated in the second half of 2025.
• In March 2025, NeoGenomics Acquires Pathline to Expand Oncology Testing. NeoGenomics, a premier cancer diagnostics company, expanded its oncology testing reach in the Northeast by acquiring Pathline, a clinical laboratory specializing in cancer diagnostics. This acquisition strengthens NeoGenomics' position in the oncology diagnostics market.
• In January 2025, GSK Acquires IDRx for $1.15 Billion. GSK announced the completion of its acquisition of IDRx, a Massachusetts-based biopharmaceutical company specializing in treatments for gastrointestinal stromal tumors (GIST). This strategic move aims to enhance GSK's oncology portfolio and address unmet needs in GI cancer treatment.

Report Coverage:

By Product Type

• Instruments & Platforms
• Assays & Kits
• Reagents & Consumables
• Software & Services

By Sample Type

• Tissue Samples
• Blood & Plasma
• Gastric Juice
• Stool Samples
• Breath Samples

By Modality

• Endoscopy & Biopsy
• Histopathology & Cytology
• Immunohistochemistry (IHC)
• Molecular & Genomic Tests
• Liquid Biopsy
• Imaging
• Biomarker Tests

By Technology

• Pathology
• Genomics
• Proteomics & Metabolomics
• Imaging Platforms
• Bioinformatics & Software Tools

By Application

• Population Screening & Risk Stratification
• Initial Diagnosis
• Cancer Staging
• Companion Diagnostics
• Treatment Monitoring
• MRD Surveillance
• Others

By End User

• Hospitals & Cancer Centers
• Diagnostic & Reference Laboratories
• Academic & Research Institutes
• Specialty GI & Endoscopy Clinics
• Contract Research Organizations (CROs) & Pharma Companies
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Roche Diagnostics
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Qiagen N.V.
• NeoGenomics Laboratories, Inc.
• Hologic, Inc.
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson and Company (BD)
• Agilent Technologies, Inc.
• Cizzle Bio, Inc.
• Illumina, Inc.
• Tempus Labs, Inc.
• Freenome, Inc.

Frequently Asked Questions (FAQs)